Cipla acquires 4 nutrition products from Wanbury for Rs 89 crore
New Delhi: Homegrown pharma firm Cipla on Saturday announced the acquisition of nutrition products portfolio from Wanbury Ltd. The company has acquired 4 brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in women's health portfolio.
The nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies, Cipla said in a regulatory filing.
This includes supplements such as multivitamins, multimineral and antioxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health, it said.
Through this newly acquired portfolio, the company shall be catering to a wide range of patient's needs including nutritional deficiencies, bone health and sexual health, it said.
The above molecules previously commercialized by Wanbury have a market size of Rs 3,100 crore in India with sales value of Rs 59.6 crore.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd